Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 14/20 | 0.63 |
| ▸ | AR | P10275 | 2/20 | 0.57 |
| ▸ | EDNRA | P25101 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038742 | 0.94 | CCR4 (0.71) | CCR4AREDNRAKDM4E | |
| SCHEMBL6038713 | 0.91 | CCR4 (0.61) | CCR4AREDNRAKDM4EMEN1 | |
| SCHEMBL6038861 | 0.91 | CCR4 (0.64) | CCR4AREDNRAKDM4E | |
| SCHEMBL6039073 | 0.91 | CCR4 (0.64) | CCR4AREDNRAKDM4E | |
| SCHEMBL6038358 | 0.90 | CCR4 (0.60) | CCR4AREDNRAKDM4EALDH1A1 | |
| SCHEMBL6039187 | 0.90 | CCR4 (0.63) | CCR4AREDNRAKDM4E | |
| SCHEMBL6038965 | 0.89 | CCR4 (0.68) | CCR4AREDNRAALDH1A1 | |
| SCHEMBL6039142 | 0.88 | CCR4 (0.60) | CCR4EDNRAKDM4EALDH1A1 | |
| SCHEMBL6038557 | 0.88 | CCR4 (0.57) | CCR4AREDNRA | |
| SCHEMBL6038430 | 0.88 | CCR4 (0.60) | CCR4AREDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | CCR4 1/4885AR 422/4885EDNRA 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.